NEW YORK (GenomeWeb News) — LabCorp today said it has licensed DNA-methylation technology from Veridex that may help it develop and market an assay to detect prostate cancer.
 
The reference lab giant said its assay will quantify in human samples the level of the gene GST-Pi, which has been linked to prostate cancer.
 
If the technology is used in conjunction with histopathology testing it may “provide a more sensitive and accurate detection of prostate cancer than histology alone,” LabCorp said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.